Physician profile
Leslie Morgan
NPI 1518218999
$2,749.49
in general payments reported to CMS, 2019-2025
38 companies · $748 in 2025
The $748 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $478 · 2022: $403 · 2023: $508 · 2024: $612 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,686 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.01 |
| Education | $182.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $721.66 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $237.52 | 2021-2025 | Iclusig, Fruzaqla, Alunbrig |
| Aveo Pharmaceuticals, INC. | $173.99 | 2024-2025 | |
| Genzyme Corporation | $165.09 | 2021-2023 | |
| Lundbeck LLC | $141.36 | 2021-2025 | Vyepti |
| Celgene Corporation | $116.85 | 2021 | |
| Eisai INC. | $106.68 | 2021-2024 | |
| Genentech USA, INC. | $105.78 | 2023-2025 | Polivy, Venclexta, Gazyva |
| Argenx US, INC. | $99.41 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $67.13 | 2022-2025 | |
| Sk Life Science, INC. | $65.21 | 2022-2024 | |
| Lilly USA, LLC | $62.60 | 2022-2024 | Emgality |
| Ucb, INC. | $56.01 | 2024-2025 | Briviact, Fintepla |
| Alexion Pharmaceuticals, INC. | $44.33 | 2021-2022 | |
| Neurelis, INC. | $40.88 | 2023-2025 | Valtoco |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.